Gradient Health: $100M valuation, IPO Readiness 53, Series A. Clinical data platform providing deidentified patient data for AI training and drug development. Track live on The IPO Stack.
Clinical data platform providing deidentified patient data for AI training and drug development.
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track Gradient Health IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
Gradient Health has not publicly announced IPO plans. Track TechStackIPO for the latest signals and subscribe to The IPO Stack for weekly updates.
Gradient Health is valued at $100M as of March 2022. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Accredited investors can access Gradient Health shares through secondary market platforms, pre-IPO investment funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace tracks available access options. Note: pre-IPO investments carry higher risk and limited liquidity compared to public market investing.
Gradient Health scores 53/100 (Grade: D) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
Gradient Health has raised $60M in total venture capital and private equity funding, with backing from Andreessen Horowitz Bio, GV, Spark Capital.
Gradient Health's notable investors include Andreessen Horowitz Bio, GV, Spark Capital, Y Combinator. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
Gradient Health is a Biotechnology company. Clinical data platform providing deidentified patient data for AI training and drug development.